Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-27T02:37:31.664Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of a Program to Reduce Hospital Ciprofloxacin Use on Nosocomial Pseudomonas aeruginosa Susceptibility to Quinolones and Other Antimicrobial Agents

Published online by Cambridge University Press:  02 January 2015

Paul P. Cook ,
Titu D. Das ,
Michael Gooch  and
Paul G. Catrou
Paul P. Cook*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Brody School of Medicine, East Carolina University, Greenville, North Carolina
Titu D. Das
Affiliation:
Division of Infectious Diseases, Department of Medicine, Brody School of Medicine, East Carolina University, Greenville, North Carolina
Michael Gooch
Affiliation:
University Health Systems of Eastern Carolina, Greenville, North Carolina
Paul G. Catrou
Affiliation:
Department of Pathology, Brody School of Medicine, East Carolina University, Greenville, North Carolina
*
Division of Infectious Diseases, Brody School of Medicine, East Carolina University, 6A Doctors Park, Greenville, NC 27834 (cookp@ecu.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

We evaluated the effect of an antimicrobial management effort to decrease ciprofloxacin use on the antibiotic susceptibility of nosocomial Pseudomonas aeruginosa isolates.

Design.

Retrospective, observational study.

Setting.

Tertiary care teaching hospital with 731 beds.

Methods.

The study was conducted between January 1, 2001, and December 31, 2007. Linear regression analyses and Student t tests were used to determine significant changes in drug use among patients and antimicrobial susceptibility patterns among nosocomial P. aeruginosa isolates during the 84-month period.

Results.

Following implementation of a program to reduce oral and intravenous use of ciprofloxacin in 2005, there was a 56.6% reduction in ciprofloxacin use (P < .001). Significant reductions in the mean percentage of nosocomial P. aeruginosa isolates that were resistant to ciprofloxacin (from 45.0% to 35.2%; P < .002) and the mean incidence of ciprofloxacin resistance (from 0.77 to 0.67 isolates recovered per 1,000 patient-days; P = .03) were noted after implementation of this program. The total quantity of antipseudomonal antibiotics consumed decreased, but the use of certain antipseudomonal antibiotics (ie, cefepime and imipenem/meropenem) increased. Among nosocomial P. aeruginosa isolates, the prevalence of imipenem/meropenem resistance increased, whereas the prevalence of cefepime resistance did not. During the 84 months of the study, there was a significant association between ciprofloxacin use and the percentage of nosocomial P. aeruginosa isolates that were resistant to ciprofloxacin (p = 0.47; P = .011), but there was no correlation between ciprofloxacin use and the incidence of ciprofloxacin resistance (p = 0.21; P = .26).

Conclusions.

Major reductions in ciprofloxacin use were associated with small but significant improvements in the rate of ciprofloxacin susceptibility among nosocomial P. aeruginosa isolates. The impact of the program on other antipseudomonal agents was variable.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 29 , Issue 8 , August 2008 , pp. 716 - 722
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Richards, MJ, Edwards, JR, Culver, DH, et al.Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887–892.CrossRefGoogle ScholarPubMed
2.Burwen, DR, Banerjee, SN, Gaynes, RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994;170:1622–1625.CrossRefGoogle ScholarPubMed
3.Quinn, JP, Dudek, EJ, DiVincenzo, CA, et al.Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 1986;154:289–294.Google Scholar
4.Neuhauser, MM, Weinstein, RA, Rydman, R, et al.Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885–888.Google Scholar
5.John, JF Jr, Fishman, NO. Programmatic role of the infectious disease physician in controlling antimicrobial cost in the hospital. Clin Infect Dis 1997;24:471–485.Google Scholar
6.Shlaes, DM, Gerding, DN, John, JF, et al.Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275–291.CrossRefGoogle Scholar
7.Rahal, JJ, Urban, C, Horn, D, et al.Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233–1237.Google Scholar
8.Cook, PP, Catrou, PG, Christie, JD, et al.Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 2004;53:853–859.Google Scholar
9.World Health Organization Collaborating Centre for Drug Statistics Methodology Web site. Available at: http://www.whocc.no/atcddd/. Accessed January 22, 2008.Google Scholar
10.Wisplinghoff, H, Bischoff, T, Tallent, SM, Seifert, H, Wenzel, RP, Edmond, MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309–317.CrossRefGoogle Scholar
11.El Amari, EB, Chamot, E, Auckenthaler, R, Pechere, JC, Van Delden, C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001;33:1859–1864.Google Scholar
12.Levin, PD, Fowler, RA, Guest, C, et al.Risk factors associated with resistance to ciprofloxacin in clinical isolates from intensive care unit patients. Infect Control Hosp Epidemiol 2007;28:331–336.Google Scholar
13.Patterson, JE, Hardin, TC, Kelly, CA, et al.Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000;21:455–458.CrossRefGoogle ScholarPubMed
14.Ntagiopoulos, PG, Paramythiotou, E, Antoniadou, A, et al.Impact of an antibiotic restriction policy on the antibiotic resistance patterns of gram-negative microorganisms in an intensive care unit in Greece. Int J Antimicrob Agents 2007;30:360–365.Google Scholar
15.Aubert, G, Carricajo, A, Vautrin, AC, et al.Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect 2005;59:83–89.Google Scholar
16.Burke, JP. Antibiotic resistance—squeezing the balloon? JAMA 1998;280:1270–1271.Google Scholar
17.MacDougall, C, Harpe, SE, Powell, JP, et al.Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005;11:1197–1204.Google Scholar
18.Rogues, AM, Dumartin, C, Amadeo, B, et al.Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007;28:1389–1395.CrossRefGoogle ScholarPubMed
19.Schwaber, MJ, De-Medina, T, Carmeli, Y. Epidemiological interpretation of antibiotic resistance studies—what are we missing? Nat Rev Microbiol 2004;2:979–983.Google Scholar
20.Monnet, DL, MacKenzie, FJ, López-Lozano, JM, et al.Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004;10:1432–1441.Google Scholar
21.Polk, RE, Johnson, CK, McClish, D, Wenzel, RP, Edmond, MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004;39:497–450.Google Scholar
22.Paramythiotou, E, Lucet, JC, Timsit, JF, et al.Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38:670–677.Google Scholar
23.Weber, SG, Gold, HS, Hooper, DC, Karchmer, AW, Carmeli, Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415–1422.Google Scholar
24.MacDougall, C, Powell, JP, Johnson, CK, Edmond, MB, Polk, RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41:435–440.CrossRefGoogle ScholarPubMed
25.Pepin, J, Saheb, N, Coulombe, MA, et al.Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.Google Scholar
26.Muto, CA, Pokrywka, M, Shutt, K, et al.A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273–280.Google Scholar
27.McCusker, ME, Harris, AD, Perencevich, E, Roghmann, MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9:730–733.Google Scholar
28.Cook, PP, Catrou, P, Gooch, M, Holbert, D. Effect of reduction in ciprofloxacin use on prevalence of methicillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. J Hosp Infect 2006;64:348–351.CrossRefGoogle ScholarPubMed
29.Valiquette, L, Cossette, B, Garant, MP, Diab, H, Pepin, J. Impact of a reduction in the use of high risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP 1/027 strain. Clin Infect Dis 2007;45(suppl 2):S112–S121.Google Scholar